French Prospective, Observational Cohort Study of Patients With Fabry Disease Treated With Migalastat

Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)

NCT03500094 ·Status: COMPLETED ·Phase: PHASE3

A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding

NCT04252066 ·Status: RECRUITING

German Observational Multicenter Study of Patients With Fabry Disease Under Chaperone Therapy With Migalastat-HCl.

NCT03135197 ·Status: COMPLETED

A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

NCT00283933 ·Status: COMPLETED ·Phase: PHASE2

MigALastat Therapy Adherence Among FABRY Patients: A Prospective Multicentral Observational Study

NCT03683966 ·Status: UNKNOWN

A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease

NCT00304512 ·Status: COMPLETED ·Phase: PHASE2

Fabry Patient's Experience Of PegunigaLsidasE Alfa Monthly Infusion

NCT05186324 ·Status: COMPLETED

A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

NCT00283959 ·Status: COMPLETED ·Phase: PHASE2

Understanding Fabry Disease Therapy Choices Through the Eyes of the Patients

NCT04804566 ·Status: COMPLETED

A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

NCT00214500 ·Status: COMPLETED ·Phase: PHASE2

Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients

NCT03614234 ·Status: COMPLETED ·Phase: PHASE3

Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

NCT00925301 ·Status: COMPLETED ·Phase: PHASE3

Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease

NCT01476163 ·Status: AVAILABLE

Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study

NCT00526071 ·Status: TERMINATED ·Phase: PHASE2

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

NCT06328608 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Fabry Disease Registry & Pregnancy Sub-registry

NCT00196742 ·Status: RECRUITING

Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease

NCT00319046 ·Status: COMPLETED ·Phase: PHASE3

A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease

NCT01298141 ·Status: COMPLETED ·Phase: PHASE3

Treatment Protocol of Replagal for Patients With Fabry Disease

NCT01031173 ·Status: NO_LONGER_AVAILABLE

Extension Study of PRX-102 for up to 60 Months

NCT01981720 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease

NCT03566017 ·Status: COMPLETED ·Phase: PHASE3

A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease

NCT04974749 ·Status: COMPLETED ·Phase: PHASE3

Fabry and Cardiomyopathy (FaCard)

NCT01429597 ·Status: WITHDRAWN

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

NCT01218659 ·Status: COMPLETED ·Phase: PHASE3

A Study of Replagal in Treatment-naïve Adults With Fabry Disease

NCT04840667 ·Status: TERMINATED ·Phase: PHASE3